日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear-cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo)

一项多中心随机 II 期试验,比较乐伐替尼联合依维莫司与卡博替尼治疗 PD-1 免疫检查点抑制剂治疗后进展的转移性透明细胞肾细胞癌患者的疗效(LenCabo)

Hahn, A W; Chahoud, J; Skelton, W P; Yuan, Y; Zurita-Saavedra, A J; Kovitz, C; Alhalabi, O; Campbell, M T; Jonasch, E; Lin, J K; Desai, M; Santos, M J M N; Hwang, H; Corn, P G; Msaouel, P; Tannir, N M

Total neoadjuvant chemotherapy combined with PD‑1 blockade and IL‑2 in MSS/pMMR locally advanced rectal cancer: short-term results of a prospective, single-arm phase II study

新辅助化疗联合PD-1阻断剂和IL-2治疗MSS/pMMR局部晚期直肠癌:一项前瞻性单臂II期研究的短期结果

Tang, Junwei; Wang, Lu; Yang, Sheng; Peng, Wen; Zhang, Yi; Zhang, Yue; Jin, Kangpeng; Wang, Xiaowei; Feng, Yifei; Sun, Yueming

PD-1/LAG-3 signaling rewires T-cells via MYC inhibition

PD-1/LAG-3信号通路通过抑制MYC重塑T细胞

Chocarro, Luisa; Fernández-Rubio, Leticia; Ausin, Karina; Blanco, Ester; Echaide, Miriam; Vilaplana, Borja; Santamaría, Enrique; Fernández-Irigoyen, Joaquín; Kochan, Grazyna; Escors, David

Lenvatinib plus transarterial chemoembolization and PD-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: a phase 2 trial and exploratory biomolecular study

乐伐替尼联合经动脉化疗栓塞术和PD-1抑制剂作为不可切除的中晚期肝细胞癌转化疗法:一项II期临床试验和探索性生物分子研究

Zhang, Xiaoyun; Cai, Haozheng; Peng, Wei; Wang, Haiqing; Wu, JiaYi; Zhu, Xinrui; Guo, Weixin; Xie, Fei; Zhang, Yu; Wang, Ming; Yu, Yu; Zhou, Yongjie; Li, Chuan; Shen, Junyi; Liu, Chang; Yang, Yu; Jiang, Xiaozhong; Li, Qiu; Chen, Weixia; Shi, Yujun; Lu, Wusheng; Sun, Xin; Feng, Xielin; Yan, Maolin; Cheng, Shuqun; Wen, Tianfu

Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study

抗PD-1抗体penpulimab联合化疗治疗复发性或转移性鼻咽癌:一项随机、双盲3期研究

Huang, Shuang; Liu, Feng; Qu, Song; Chen, Lisha; Zhou, Ping; Qu, Shenhong; Ai, Xiaohong; Chen, Yong; Liu, Meilian; Wang, Rensheng; Chan, Kelvin Kw; Zhang, Peng; Hu, Chunhong; Wen, Jiyu; Zhang, Jian; Lin, Qin; Li, Xiaojiang; Gu, Kangsheng; Xiang, Li; Wang, Dongxia; Li, Jingao; Lin, Daren; Hu, Desheng; Ding, Jianwu; Wang, Siyang; Huang, Xiaoming; Wang, Lin; Jin, Feng; Pfister, David G; Mak, Milena Perez; Marchi, Pedro Rafael Martins de; Jiang, Yi; Yang, Haihua; Hu, Xiaoye; Liu, Tianrun; Wu, Dehua; Shreenivas, Aditya; Oliveira, Thiago Bueno de; Silva, Carlos Eduardo Baston; Alves, Gustavo Vasconcelos; Li, Xianming; Yao, Zhifang; Lu, Dongmei; Hu, Mingxiu; Wang, Zhongmin Maxwell; Li, Baiyong; Xia, Michelle; Chen, Xiaozhong; Hu, Chaosu; Xu, Tingting

Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy.

抗PD-1治疗后,与HIV病毒库相关的先天性抗病毒和免疫功能会衰退。

Talla Aarthi, Azevedo Joao L L C, Latif Muhammad Bilal, Enriquez Ana B, Sanchez Gabriela Pacheco, Pelletier Adam N, Bal Saswat Kumar, Kumari Sangeeta, Schuch Viviane, Ghneim Khader, Rhodes Ajantha, Maldarelli Frank, Yarchoan Robert, Lurain Kathryn, Ramaswami Ramya, Sharon Elad, Hess Bruce W, D'Amico Leonard, Martinez-Picado Javier, Chomont Nicolas, Lewin Sharon R, Deeks Steven G, Fling Steven P, Cheever Martin A, Uldrick Thomas S, Sharma Ashish A, Sekaly Rafick-Pierre

Inhibitory PD-1 axis maintains high-avidity stem-like CD8(+) T cells

抑制性PD-1轴维持高亲和力干细胞样CD8(+) T细胞

Hor, Jyh Liang; Schrom, Edward C; Wong-Rolle, Abigail; Vistain, Luke; Shang, Wanjing; Dong, Qiang; Zhao, Chen; Jin, Chengcheng; Germain, Ronald N

PD-1 Blockade-Induced DKK1 Expression by CD8+ T Cells Promotes Blood-Brain Barrier Permeabilization

PD-1阻断诱导的CD8+ T细胞DKK1表达促进血脑屏障通透性增加

Deo, Abhilash; Levin, Sapir; Buxbaum, Chen; Benguigui, Madeleine; Manobla, Bar; Saar, Galit; Bosak, Noam; Bergmann, Eyal; Eran, Ayelet; Grinfeld, Anat; Harel, Michal; Lahav, Coren; Raviv, Ziv; Daher, Sameh; Zer, Alona; Reuter, Julia Helena; Heuβel, Claus Peter; Christopoulos, Petros; Yizhak, Keren; Shaked, Yuval

Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial

手术可切除的促纤维增生性黑色素瘤新辅助PD-1阻断治疗:SWOG S1512 II期试验的A组队列

Kendra, Kari L; Bellasea, Shay L; Eroglu, Zeynep; Hu-Lieskovan, Siwen; Campbell, Katie M; Carson, William E 3rd; Wada, David A; Plaza, Jose A; In, Gino K; Ikeguchi, Alexandra; Hyngstrom, John; Brohl, Andrew S; Chmielowski, Bartosz; Khushalani, Nikhil I; Markowitz, Joseph; Monroe, Marcus; Contreras, Carlo M; Bowles, Tawnya; Norman, Kurt; Medina, Egmidio; Gonzalez, Cynthia R; Baselga-Carretero, Ignacio; Garcilazo, Ivan Perez; Vega-Crespo, Agustin; Chen, Jia Ming; Deen, Nataly Naser Al; Patel, Sapna P; Grossmann, Kenneth F; Sondak, Vernon K; Sharon, Elad; Moon, James; Wu, Michael C; Ribas, Antoni

TIMELESS Promotes LUAD Growth via Suppressing Transferrin-Mediated Ferroptosis and Reprograms the Tumor Microenvironment against Anti-PD-1 Immunotherapy.

TIMELESS 通过抑制转铁蛋白介导的铁死亡促进 LUAD 生长,并重编程肿瘤微环境以对抗抗 PD-1 免疫疗法。